Leah Marie Rivers, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1097 Hospital Dr, St Johnsbury, VT 05819 Phone: 802-748-6166 |
Olivia Lamothe, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2895 Old Silo Rd, St Johnsbury, VT 05819 Phone: 802-274-7604 |
Jennifer Ruth Jones, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1097 Hospital Dr, St Johnsbury, VT 05819 Phone: 802-748-6166 |
Bonnie Baraw, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1097 Hospital Dr, St Johnsbury, VT 05819 Phone: 802-748-6166 Fax: 802-748-3316 |
Karen Christine Webb, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 20 Russell Ave, St Johnsbury, VT 05819 Phone: 802-751-9365 |
News Archive
Merck KGaA, Darmstadt, Germany, and Pfizer Inc. today announced that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved BAVENCIO (avelumab, genetically recombinant Injection 200mg/mL for intravenous use) as the first and only treatment indicated for curatively unresectable Merkel cell carcinoma (MCC), a rare and aggressive cancer, in Japan.
Tethys Bioscience, a privately held company, announced today that it has closed a $25 million Series D round of financing led by aeris CAPITAL AG and including Wasatch Advisors as a new investor. All current investors, including MDV-Mohr Davidow Ventures, Kleiner Perkins Caulfield & Byers and Intel Capital participated in the round. Tethys also announced that it has appointed George Rehm, Managing Partner of aeris CAPITAL, to the Tethys Board of Directors.
Low concentration of fish oil in the blood and lack of physical activity may contribute to the high levels of depressed mood among soldiers returning from combat, according to researchers, including a Texas A&M University professor and his former doctoral student.
Amakem NV today announced it has raised €18m with a syndicate of leading life sciences investors to advance its ophthalmology drug development portfolio and progress its lead candidate, AMA0076 for glaucoma, to clinical proof of concept.
› Verified 4 days ago